Isocitrate Dehydrogenase (IDH) Inhibitors

Isocitrate Dehydrogenase (IDH) inhibitors are a class of pharmaceutical compounds that target and inhibit the activity of the Isocitrate Dehydrogenase enzyme This enzyme plays a crucial role in cellular metabolism and is frequently mutated in certain types of cancers By specifically targeting and inhibiting IDH these inhibitors have shown promising results in slowing or halting the growth of cancer cells harboring IDH mutations This targeted therapy holds great potential for the treatment of various cancers and represents a significant advancement in precision medicine Our company specializes in developing and providing high-quality IDH inhibitors to support cancer research and therapeutic advancements

Catalog Number	Chemical Name	CAS #	Price
EI-0134	AG-120 (Ivosidenib)	1448347-49-6	Online Inquiry
EI-0137	AG-221 (Enasidenib)	1446502-11-9	Online Inquiry
EI-0138	AG-881	1644545-52-7	Online Inquiry
EI-0139	AGI-5198	1355326-35-0	Online Inquiry
EI-0140	AGI-6780	1432660-47-3	Online Inquiry
EI-0340	BAY-1436032	1803274-65-8	Online Inquiry

Application

Isocitrate Dehydrogenase (IDH) inhibitors have wide-ranging applications in both research and medicine In the field of research these inhibitors are essential tools for studying and understanding the role of IDH enzymes in various biological processes By inhibiting the activity of IDH enzymes scientists can investigate the downstream effects on cellular metabolism gene expression and disease development

In medicine IDH inhibitors hold promise as potential treatments for certain types of cancer Mutations in IDH enzymes have been identified in several cancers and these inhibitors can specifically target and block the mutated enzymes inhibiting their oncogenic effects Research has shown that IDH inhibitors have the potential to slow tumor growth induce differentiation of cancer cells and enhance sensitivity to other therapeutic agents

The development of IDH inhibitors also opens up possibilities for personalized medicine As these inhibitors target specific mutations they have the potential to be used as precision therapies tailored to patients with IDH-mutated cancers This targeted approach can minimize side effects and improve treatment outcomes

Overall the diverse applications of IDH inhibitors in research and medicine highlight their potential to advance our understanding of biology and provide new treatment options for cancer patients

Please note that all services are for research use only. Not intended for any clinical use.

Isocitrate Dehydrogenase (IDH) Inhibitors